Project Grant R01DA060499
Award Date
9/30/24
Completion Date
7/31/29
Dollars Obligated
$708K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is aimed at implementing a low-threshold Hepatitis C (HCV) treatment strategy in a jail setting. The $252,042 award, effective September 15, 2024, will support a pilot study at Rhode Island Hospital to evaluate the feasibility and effectiveness of the "MINMON-J" approach, which modifies a minimal monitoring HCV treatment protocol for use...
The National Institute on Drug Abuse (NIDA) awarded a Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) totaling $1,499,606.00 to the Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, with a project period from September 30, 2024 to July 31, 2029. The goal of this project is to characterize health outcomes from birth to 5 years of age in children born to individuals with opioid use disorder, identify disparities across populations,...
This Project Grant award of $1,744,696.00, provided by the Centers for Disease Control and Prevention's National Center for Injury Prevention and Control under the Injury Prevention and Control Research and State and Community Based Programs (CFDA 93.136), is for a 3-year research project to assess the implementation and outcomes of state prenatal drug use laws. The primary awardee, The Johns Hopkins University, will lead the research, which includes designing qualitative interview guides,...
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400 pregnancies...
The National Institute on Drug Abuse (NIDA) awarded a $1,381,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Nebraska Medical Center (UNMC) to explore sex differences in the establishment and maintenance of HIV/SIV reservoirs in the context of opioid use. The overarching goal is to delineate the role of sex factors in seeding and establishing viral reservoirs (Aim 1) and determine the location, abundance, and persistence of viral reservoirs...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
This $1,210,300 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel polyvalent HIV vaccines designed to prevent intravenous transmission in people who inject drugs (PWID). The research team at Beth Israel Deaconess Medical Center, Inc. (BIDMC) will create diverse HIV envelope-based vaccines and evaluate their ability to rapidly clear multiple viral strains in animal models, with...
The National Institute on Drug Abuse (NIDA) awarded a $687,416 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA. The grant supports research to develop therapeutically effective latency-promoting agents (LPAs) that can "block" HIV reactivation and "lock" HIV in a silenced state, even in the presence of addictive substances, for people living...
This federal Project Grant award of $435,313 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop a cost-based epidemiological planning tool to guide public health response to the combined HIV, hepatitis C (HCV), and opioid use disorder (OUD) epidemics. Specifically, the project will: 1) Create an interactive, web-based dashboard to assist policymakers in planning an effective response and provide improved estimates...